{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-09-25",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "product_ndc": "27241-300",
      "generic_name": "Topiramate",
      "labeler_name": "Ajanta Pharma USA Inc.",
      "brand_name": "Topiramate",
      "active_ingredients": [
        {
          "name": "TOPIRAMATE",
          "strength": "200 mg/1"
        }
      ],
      "finished": true,
      "packaging": [
        {
          "package_ndc": "27241-300-30",
          "description": "30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (27241-300-30)",
          "marketing_start_date": "20250902",
          "sample": false
        }
      ],
      "listing_expiration_date": "20271231",
      "openfda": {},
      "marketing_category": "ANDA",
      "dosage_form": "CAPSULE, EXTENDED RELEASE",
      "spl_id": "a64af809-588a-4986-93e6-99fe5a7537cf",
      "product_type": "HUMAN PRESCRIPTION DRUG",
      "route": [
        "ORAL"
      ],
      "marketing_start_date": "20250902",
      "product_id": "27241-300_a64af809-588a-4986-93e6-99fe5a7537cf",
      "application_number": "ANDA219564",
      "brand_name_base": "Topiramate",
      "pharm_class": [
        "Cytochrome P450 2C19 Inhibitors [MoA]",
        "Cytochrome P450 3A4 Inducers [MoA]",
        "Decreased Central Nervous System Disorganized Electrical Activity [PE]"
      ]
    }
  ]
}